范可尼贫血中采用无放疗预处理的无体外处理单倍体造血细胞移植:中国血液与骨髓移植登记组回顾性分析
该回顾性分析纳入中国11个中心2013至2021年间56例范可尼贫血患者,分析无体外处理单倍体造血细胞移植联合无放疗预处理的结果。30天中性粒细胞植入累积发生率为96.4%,100天血小板植入为85.5%,中位随访2.4年总生存为80.9%、无事件生存为79.3%。急性移植物抗宿主病II-IV度和III-IV度发生率分别为55.4%和42.9%,3年慢性移植物抗宿主病为34.7%。
要点
- 无体外处理单倍体移植联合无放疗预处理在范可尼贫血中获得有利的植入与生存。
- 急性移植物抗宿主病II-IV度和III-IV度发生率分别为55.4%和42.9%,慢性移植物抗宿主病3年累积发生率为34.7%。
- 作者提出考虑无体外处理单倍体移植时,可采用低强度无放疗预处理并加强移植物抗宿主病预防。
核心结论
- 无体外处理单倍体造血细胞移植联合以氟达拉滨和低剂量环磷酰胺±白消安为基础的无放疗预处理,在范可尼贫血患者中取得有利的植入和生存,但急性与慢性移植物抗宿主病发生率相对较高。
研究设计与样本
- 回顾性分析中国11个中心2013年至2021年间56例范可尼贫血患者,接受无体外处理单倍体造血细胞移植联合无放疗预处理。
主要发现
- 30天中性粒细胞植入平均(SD)累积发生率为96.4%(0.08%),100天血小板植入为85.5%(0.24%)。
- 中位(范围)随访2.4(0.2-5.8)年,总生存平均(SD)为80.9%(5.5%),无事件生存为79.3%(5.6%)。
- 急性移植物抗宿主病II-IV度平均(SD)发生率为55.4%(0.45%),III-IV度为42.9%(0.45%)。
- 3年慢性移植物抗宿主病平均(SD)累积发生率为34.7%(0.86%),中重度慢性移植物抗宿主病为9.0%(0.19%)。
关键数值与推荐
- 预处理方案为以氟达拉滨和低剂量环磷酰胺±白消安为基础的无放疗方案。
临床怎么用
- 作者提出,在考虑对范可尼贫血患者进行无体外处理单倍体造血细胞移植时,可采用低强度无放疗预处理并加强移植物抗宿主病预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haematopoietic cell transplantation (HCT) is the only curative treatment for haematological complications in patients with Fanconi anaemia (FA). Haploidentical (haplo-) HCT is a promising alternative for FA. We aimed to analyse the outcomes of unmanipulated haplo-HCT in patients with FA with radiation-free conditioning. A total of 56 patients from 11 centres between 2013 and 2021 in China were retrospectively analysed. The mean (SD) cumulative incidence was 96.4% (0.08%) for 30-day neutrophil engraftment and 85.5% (0.24%) for 100-day platelet engraftment. With a median (range) follow-up of 2.4 (0.2-5.8) years, favourable mean (SD) overall survival of 80.9% (5.5%) and event-free survival of 79.3% (5.6%) were achieved. The mean (SD) incidences of acute graft-versus-host disease (aGvHD) Grade II-IV and Grade III-IV were 55.4% (0.45%) and 42.9 (0.45%) respectively. The mean (SD) cumulative incidence of 3-year chronic graft-versus-host disease (cGvHD) was 34.7% (0.86%) and that of moderate-to-severe cGvHD was 9.0% (0.19%). Our data demonstrate that in unmanipulated haplo-HCT for patients with FA, radiation-free regimens based on fludarabine and low-dose cyclophosphamide ± busulfan achieved favourable engraftment and survival with relatively high incidences of aGvHD and cGvHD. These results prompt the use of low-intensity conditioning without radiation and intensive GvHD prophylaxis when considering unmanipulated haplo-HCT in patients with FA.
引用
- Xu L, Lu Y, Hu S, et al. Unmanipulated haploidentical haematopoietic cell transplantation with radiation-free conditioning in Fanconi anaemia: A retrospective analysis from the Chinese Blood and Marrow Transplantation Registry Group. Br J Haematol. 2022. PMID: 35989315. doi:10.1111/bjh.18408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。